EGFR and lung cancer: The availability of effective systemic options can tip the risk–benefit balance in favor of surgery – for example, resecting an intramedullary metastasis in a lung cancer patient responding to an EGFR inhibitor can prevent paralysis and yield survival beyond historically grim expectations [12].